

**From:** [Jarvis, Candace](#)  
**To:** [Monser, Martha](#)  
**Cc:** [Jarvis, Candace](#); [Byrnes, Andrew](#); [Hornatko-Munoz, Adrienne](#); [Rehkopf, Carol](#)  
**Subject:** BLA 125694/0| AveXis Inc| Reference Product Exclusivity  
**Date:** Wednesday, December 19, 2018 10:08:58 AM  
**Attachments:** [125694 reference product determination.CR.PDF](#)  
[image013.png](#)  
**Importance:** High

---

Good morning,

This email is to provide you with the review memo for reference product exclusivity for BLA 125694, AveXis, Inc.

I do apologize for sending this directly to you, but I could not locate the email address for CBER ADRM that didn't house the email addresses of 55 recipients . I reached out to Carol , but she was having Outlook issues.

Please let me know if there is anything else that is needed for this process.

*Regards,*

***Candace N. Jarvis***  
*Regulatory Project Manager*  
*Center for Biologics Evaluation and Research*  
**Office of Tissues and Advanced Therapies**  
**U.S. Food and Drug Administration**  
Tel: 240-402-8315  
[candace.jarvis@fda.hhs.gov](mailto:candace.jarvis@fda.hhs.gov)



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.